Ignite Creation Date:
2024-05-06 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06157983
Status:
RECRUITING
Last Update Posted:
2024-03-19
First Post:
2023-11-23
Brief Title:
Evaluation of Cascade Screening for Elevated Lipoproteina
Sponsor:
Karolinska Institutet
Organization:
Karolinska Institutet
Study Overview
Official Title:
Evaluation of Cascade Screening for Elevated Lipoproteina in Relatives to Patients With Atherosclerotic Coronary Artery Disease
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LipoaScreen
Brief Summary:
The aim of the current project is to evaluate the penetrance of elevated plasma Lpa levels in patients with atherosclerotic coronary artery disease to their first- and second-degree biological relatives based on data from a clinical health care development project
Detailed Description:
An elevated plasma level of lipoproteina Lpa is an independent and causative risk factor for atherosclerotic cardiovascular disease The Lpa plasma level is predominantly genetically determined via a complex hereditary pattern of the LPA gene and remains relatively constant throughout an individuals entire life cycle The relationship between plasma Lpa and the risk for a cardiovascular event has been shown to be linear
Cascade screening ie screening of biological relatives of the first detected patient index with a disease in a family is an effective approach to identify and diagnose new patients with hereditary diseases The method has been shown to be cost-effective for the most common genetically caused dyslipidemia familial hypercholesterolemia but the knowledge if cascade screening would be an effective method to screen for elevated plasma Lpa is not known
The aim of the current project is to evaluate the penetrance of elevated plasma Lpa levels in patients with atherosclerotic coronary artery disease to their first- and second-degree biological relatives The study will be based on results from a clinical health care development project in which patients who have had their plasma Lpa measured in the clinical routine will be asked to participate in the project The participating patients invite their relatives to participate in the cascade screening and to measure their plasma Lpa levels Six Swedish hospitals participate in the project and 750 patients with atherosclerotic coronary artery disease be included and divided into three strata according to their plasma Lpa level low 70 nmolL intermediate 70-169 nmolL high 170 nmolL The indexes will in turn invite 1200 first- and second-degree relatives to have their plasma Lpa measured
A scientific evaluation of the health care development project will be performed to study the penetrance of elevated plasma Lpa levels in indexes to their relatives
Cascade screening ie screening of biological relatives of the first detected patient index with a disease in a family is an effective approach to identify and diagnose new patients with hereditary diseases The method has been shown to be cost-effective for the most common genetically caused dyslipidemia familial hypercholesterolemia but the knowledge if cascade screening would be an effective method to screen for elevated plasma Lpa is not known
The aim of the current project is to evaluate the penetrance of elevated plasma Lpa levels in patients with atherosclerotic coronary artery disease to their first- and second-degree biological relatives The study will be based on results from a clinical health care development project in which patients who have had their plasma Lpa measured in the clinical routine will be asked to participate in the project The participating patients invite their relatives to participate in the cascade screening and to measure their plasma Lpa levels Six Swedish hospitals participate in the project and 750 patients with atherosclerotic coronary artery disease be included and divided into three strata according to their plasma Lpa level low 70 nmolL intermediate 70-169 nmolL high 170 nmolL The indexes will in turn invite 1200 first- and second-degree relatives to have their plasma Lpa measured
A scientific evaluation of the health care development project will be performed to study the penetrance of elevated plasma Lpa levels in indexes to their relatives
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None